Synthetic oligonucleotides: the development of antisense therapeutics.

@article{Monteith1999SyntheticOT,
  title={Synthetic oligonucleotides: the development of antisense therapeutics.},
  author={David K B Monteith and Arthur A. Levin},
  journal={Toxicologic pathology},
  year={1999},
  volume={27 1},
  pages={8-13}
}
Antisense therapeutics using synthetic oligodeoxynucleotides (ODNs) are currently being evaluated in clinical trials for cancer, inflammation, and viral diseases. These macromolecules afford a unique opportunity to treat disease at the molecular level. The specificity of these compounds is derived from the genetic code and Watson-Crick base pairing, utilizing an antisense paradigm for the inhibition of translation and the regulation of protein expression. Currently, most antisense ODNs in… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

A status report on RNAi therapeutics

View 8 Excerpts
Highly Influenced

CpG Oligodeoxynucleotides as TLR9 Agonists

View 3 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…